Increased incidence of lobular breast cancer in women treated with hormone replacement therapy: Implications for diagnosis, surgical and medical treatment

Endocrine-Related Cancer

Volumn 14, Issue 3, 2007, Pages 549-567

  Biglia, Nicoletta ^a   Mariani, Luca ^a   Sgro, Luca ^a   Mininanni, Paola ^a   Moggio, Giulia ^a   Sismondi, Piero ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; ESTROGEN RECEPTOR; GESTAGEN; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53; TAMOXIFEN; TAXANE DERIVATIVE; VASCULOTROPIN;

ACCURACY; ASPIRATION BIOPSY; BIOPSY; BREAST CANCER; BREAST SURGERY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; DISEASE FREE SURVIVAL; ECHOGRAPHY; FOLLOW UP; GASTROINTESTINAL TRACT; HISTOLOGY; HORMONE SUBSTITUTION; HUMAN; LYMPHATIC SYSTEM; MAMMOGRAPHY; MASTECTOMY; METASTASIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PERITONEUM; PROGNOSIS; RETROPERITONEUM; REVIEW; RISK; SENTINEL LYMPH NODE BIOPSY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY, FINE-NEEDLE; BREAST NEOPLASMS; CARCINOMA, LOBULAR; COMBINED MODALITY THERAPY; ESTROGEN REPLACEMENT THERAPY; FEASIBILITY STUDIES; FEMALE; HUMANS; INCIDENCE; INTRAOPERATIVE PERIOD; MAGNETIC RESONANCE IMAGING; MAMMOGRAPHY; MASTECTOMY, SEGMENTAL; MASTECTOMY, SIMPLE; NEOPLASM INVASIVENESS; PROGNOSIS; RISK ASSESSMENT; SENTINEL LYMPH NODE BIOPSY; ULTRASONOGRAPHY, MAMMARY;

EID: 35948979724     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/ERC-06-0060     Document Type: Review

References (121)

1. Abd El-Rehim DM, Pinder SE, Paish CE, Bell JA, Rampaul RS, Blamey RW, Robertson JFR, Nicholson RI & Ellis IO 2004 Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. British Journal of Cancer 91 1532-1542.
2. Allemani C, Sant M, Berrino F, Aareleid T, Chaplain G, Coebergh JW, Colonna M, Contiero P, Danzon A & Federico M 2004 Prognostic value of morphology and hormone receptor status in breast cancer - a population-based study. British Journal of Cancer 91 1263-1268.
3. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B & Women's Health Initiative Steering Committee 2004 Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291 1701-1712.
4. Arpino G, Bardou VJ, Clark GM & Elledge RM 2004 Infiltrating lobular carcinoma of the breast:tumor characterictcs and clinical outcome. Breast Cancer Research 6 149-156.
5. Bamias A, Baltayiannis G, Kamina S, Fatouros M, Lymperopoulos E, Agnanti N, Tsianos E & Pavlidis N 2001 Rectal metastases from lobular carcinoma of the breast: report of a case and literature review. Annals of Oncology 12 715-718.
6. Bedrosian I, Mick R, Orel SG, Schnall M, Reynolds C, Spitz FR, Callans LS, Buzby GP, Rosato EF & Fraker DL 2003 Changes in the surgical management of patients with breast carcinoma based on preoperative magnetic resonance imaging. Cancer 98 468-473.
7. Beral V & Million Women Study Collaborators 2003 Breast cancer and hormone replacement therapy in the Million Women Study. Lancet 362 419-427.
8. Biglia N, Sgro L, Defabiani E, De Rosa G, Ponzone R, Marenco D & Sismondi P 2005 The influence of hormone replacement therapy on the pathology of breast cancer. European Journal of Surgical Oncology 31 467-472.
9. Boetes C, Veltman J, Van Die L, Bult P, Wobbes T & Barentsz JO 2004 The role of MRI in invasive lobular carcinoma. Breast Cancer Research and Treatment 36 31-37.
10. Borst MJ & Ingold JA 1993 Metastatic patterns of invasive lobular versus invasive ductal carcinoma of the breast. Surgery 114 637-641.
11. Bouvet M, Ollila DW, Hunt KK, Babiera GV, Spitz FR, Giuliano AE, Strom EA, Ames FC, Ross MI & Singletary SE 1997 Role of conservation therapy for invasive lobular carcinoma of the breast. Annals of Surgical Oncology 4 650-654.
12. Bumpers HL, Hassett JM Jr, Penetrante RB, Hoover EL & Holyoke ED 1993 Endocrine organ metastases in subjects with lobular carcinoma of the breast. Archives of Surgery 128 1344-1347.
13. Butler RS, Venta LA, Wiley EL, Ellis RL, Dempsey PJ & Rubin E 1999 Sonographic evaluation of infiltrating lobular carcinoma. American Journal of Roentgenology 172 325-330.
14. Caly M, Genin P, Ghuzlan AA, Elie C, Freneaux P, Klijanienko J, Rosty C, Sigal-Zafrani B, Vincent-Salomon A & Douggaz A 2004 Analysis of correlation between mitotic index, MIB1 score and S-phase fraction as proliferation markers in invasive breast carcinoma. Methodological aspects and prognostic value in a series of 257 cases. Anticancer Research 24 3283-3288.
15. Chagpar A, Martin RCG II, Hagerndoorn LJ, Chao BSC & McMasters KM 2004 Lumpectomy margins are affected by tumour size and histologic subtype but not by biopsy technique. American Journal of Surgery 188 399-402.
16. Chen CL, Weiss NS, Newcomb P, Barlow W & White E 2002 Hormone replacement therapy in relation to breast cancer. JAMA 287 734-741.
17. Chen WY, Manson JE, Hankinson SE, Rosner B, Holmes MD, Willett WC & Colditz GA 2006 Unopposed estrogen therapy and the risk of invasive breast cancer. Archives of Internal Medicine 166 1027-1032.
18. Chintana PP, Helvie MA & Adler DD 1995 Invasive lobular Carcinoma: sonographic appearance and role of sonography in improving diagnostic sensitivity. Radiology 195 231-234.
19. Chung MA, Cole B, Wanebo HJ, Bland KI & Chang HR 1997 Optimal surgical treatment of invasive lobular carcinoma of the breast. Annals of Surgical Oncology 20 545-550.
20. Classe JM, Loussouarn D, Campion L, Fiche M, Curtet C, Dravet F, Pioud R, Rousseau C, Resche J & Sagan C 2004 Validation of axillary sentinel lymph node detection in the staging of early lobular invasive breast carcinoma: a prospective study. Cancer 100 935-941.
21. Cocquyt V & Van Belle S 2005 Lobular carcinoma in situ and invasive lobular cancer of the breast. Current Opinion in Obstetrics and Gynecology 17 55-60.
22. Cocquyt VF, Blondeel PN, Depypere HT, Praet MM, Schelfhout VR, Silva OE, Hurley J, Serreyn RF, Daems KK & Van Belle SJ 2003 Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma. European Journal of Surgical Oncology 29 361-367.
23. Colditz GA & Rosner B 1998 Use of estrogen plus progestin is associated with greater increase in breast cancer risk than estrogen alone. American Journal of Epidemiology 147 64S.
24. Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, Hennekens C, Rosner B & Speizer FE 1995 The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. New England Journal of Medicine 332 1589-1593.
25. Coradini D, Pellizzaro C, Veneroni S, Ventura L & Daidone MG 2002 Infiltrating ductal and lobular breast carcinomas are characterised by different interrelationships among markers related to angiogenesis and hormone dependence. British Journal of Cancer 87 1105-1111.
26. Cornford EJ, Wilson AR, Athanassiou 4E, Galea M, Ellis IO, Elston CW & Blamey RW 1995 Mammographic features of invasive lobular and invasive ductal carcinoma of the breast: a comparative analyisis. British Journal of Radiology 68 450-453.
27. Creager AJ & Geisinger KR 2002 Intraoperative evaluation of sentinel lymph nodes for breast carcinoma: current methodologies. Advances in Anatomic Pathology 9 233-243.
28. Cristofanilli M, Gonzalez-Angulo A, Sneige N, Kau SW, Broglio K, Theriault RL, Valero V, Buzdar AU, Kuerer H & Buccholz TA 2005 Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. Journal of Clinical Oncology 23 41-48.
29. Daling JR, Malone KE, Doody DR, Voigt LF, Bernstein L, Coates RJ, Marchbanks PA, Norman SA, Weiss LK & Ursin G 2002 Relation of regimens of combined hormone replacement therapy to lobular,ductal, and other histologic types of breast carcinoma. Cancer 95 2455-2464.
30. van Diest PJ, van der Wall E & Baak JP 2004 Prognostic value of proliferation in invasive breast cancer: a review. Journal of Clinical Pathology 57 675-681.
31. Dixon JM, Anderson TJ, Page DL, Lee D & Duffy SW 1982 Infiltrating lobular carcinoma of the breast. Histopathology 6 149-161.
32. Du Toit RS, Cocker AP, Ellis IO, Elston CW, Nicholson RL, Robertson JFR & Blamey RW 1991 An evaluation of differences in prognosis, recurrence patterns and receptor status between invasive lobular and other invasive carcinomas of the breast. European Journal of Surgical Oncology 17 251-257.
33. Esserman L, Wolverton D & Hylton N 2002 Magnetic resonance imaging for primary breast cancer management: current role and new applications. Endocrine-Related Cancer 9 141-153.
34. Evans N & Lyons K 2000 The use of ultrasound in the diagnosis of invasive lobular carcinoma of the breast less than 10 mm size. Clinical Radiology 55 261-263.
35. Evans WP, Warren Burhenne LJ, Laurie L, O'Shaughnessy KF & Castellino RA 2002 Invasive lobular carcinoma of the breast: mammographic characteristics and computer-aided detection. Radiology 225 182-189.
36. Fisher ER, Gregorio RM, Fisher B, Redmond C, Vellios F & Sommers SC 1975 The pathology of invasive breast cancer: a syllabus derived from findings of the National Surgical Adjuvant Breast Project (protocol No. 4). Cancer 36 1-85.
37. Fisher U, Kopka L & Grabbe E 1999 Breast carcinoma: effect of preoperative contrast-enhanced MR imaging on the therapeutic approach. Radiology 213 881-888.
38. Fleming FJ, Hill AD, Mc Dermott EW, O'Doherty A, O'Higgins NJ & Quinn CM 2004 Intraoperative margin assessment and re-excision rate in breast conserving surgery. European Journal of Surgical Oncology 30 233-237.
39. Frolik D, Caduff R & Varga Z 2001 Pleomorphic lobular carcinoma of the breast: its cell kinetics, expression of oncogenes and tumour suppressor genes compared with invasive ductal carcinomas and classical infiltrating lobular carcinomas. Histopathology 39 503-513.
40. Le Gal M, Ollivier L, Asselain B, Meunier M, Laurent M, Vielh P & Neuenschwander S 1992 Mammographic features of 455 invasive lobular carcinomas. Radiology 185 705-708.
41. Goldflam K, Hunt KK, Gershenwald JE, Singletary SE, Mirza N, Kuerer HM, Babiera GV, Ames FC, Ross MI, Feig BW et al. 2004 Contralateral prophylactic mastectomy. Predictors of significant histologic findings. Cancer 101 1977-1986.
42. Golshan M, Fung BB, Wiley E, Wolfaman J, Rademaker A & Morrow M 2004 Prediction of breast cancer size by ultrasound, mammography and core biopsy. Breast 13 265-271.
43. Goyal A, Newcombe RG, Mansel RE, Chetty U, Ell P, Fallowfield L, Kissin M, Sibbering M & ALMANAC Trialists Group 2004 Sentinel lymph node biopsy in patients with multifocal breast cancer. European Journal of Surgical Oncology 30 475-479.
44. Greendale GA, Reboussin BA, Sie A, Singh HR, Olson LK, Gatewood O, Bassett LW, Wasilauskas C, Bush T & Barrett-Connor E 1999 Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators. Annals of Internal Medicine 130 262-269.
45. Gupta A, Deshpande CG & Badve S 2003 Role of E-cadherins in development of lymphatic tumor emboli. Cancer 97 2341-2347.
46. Gurkan A, Erdogan G, Erdogan O, Pestereli E, Ogus M, Karaveli S & Colak T 2004 Expression of c-erbB-2 and p53 in breast carcinoma patients: comparison with traditional prognostic factors and survival. Journal of International Medical Research 32 455-464.
47. Haffty BG, Perrotta PL, Ward B, Moran M, Beinfield M & McKhann C 1997 Conservatively treated breast cancer: outcome by histological type. Breast Journal 3 7-14.
48. Helvie MA, Paramagul C, Oberman HA & Adler DD 1993 Invasive lobular carcinoma: imaging features and clinical detection. Investigative Radiology 28 202-207.
49. Hemminki E, Kennedy DL, Baum C & McKinlay SM 1988 Prescribing of noncontraceptive estrogens and progestins in the United States, 1974-1986. American Journal of Public Health 78 1479-1481.
50. Hofseth LJ, Raafat AM, Osuch JR, Pathak DR, Slomski CA & Haslam SZ 1999 Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. Journal of Clinical Endocrinology and Metabolism 84 4559-4565.
51. Holland PA, Shah A, Howell A, Baildam AD & Bundred NJ 1995 Lobular carcinoma of the breast managed by breast-conserving therapy. British Journal of Surgery 82 1364-1366.
52. Horiguchi J, Iino Y, Takei H, Maemura M, Yokoe T, Niibe H, Yamakawa M, Nakajima T, Oyama T & Morishita Y 1999 Surgical margin and breast recurrence after breast-conserving therapy. Oncology Reports 6 135-138.
53. Horst KC, Smitt MC, Goffinet DR & Carlson RW 2005 Predictors of local recurrence after breast-conservation therapy. Clinical Breast Cancer 5 425-438.
54. Hussien M, Lioe TF, Finnegan J & Spence AJ 2003 Surgical treatment for invasive lobular carcinoma of the breast. Breast 12 23-35.
55. Hwang S, Ioffe O, Lee I, Waisman J, Cangiarella J & Simsir A 2004 Cytologic diagnosis of invasive lobular carcinoma: factors associated with negative and equivocal diagnoses. Diagnostic Cytopathology 31 87-93.
56. Ismail PM, Asmato P, Solyal SM, DeMayo FJ, Coneely OM, O'Malley BW & Lydon JP 2003 Progesterone involvement in breast development and tumorigenesis - as revealed by progesterone receptor 'knockout' and 'knockin' mouse models. Steroids 68 779-787.
57. Jimeno A, Amador ML, Gonzalez-Cortijo L, Tornamira MV, Ropero S, Valentin V, Hornedo J, Cortes-Funes H & Colomer R 2004 Initially metastatic breast carcinoma has a distinct disease pattern but an equivalent outcome compared with recurrent metastatic breast carcinoma. Cancer 100 1833-1842.
58. Kaufmann M, von Minckwitz G, Smith R, Valero V, Gianni L, Eiermann W, Howell A, Costa SD, Beuzeboc P & Untch M 2003 International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. Journal of Clinical Oncology 21 2600-2608.
59. Kneeshaw PJ, Turnbull LW, Smith A & Drew PJ 2003 Dynamic contrast enhanced magnetic resonance imaging aids the surgical management of invasive lobular breast cancer. European Journal of Surgical Oncology 29 32-37.
60. Korhonen T, Huhtala H & Holli K 2004 A comparison of the biological and clinical features of invasive lobular and ductal carcinomas of the breast. Breast Cancer Research and Treatment 85 23-29.
61. Krecke KN & Gisvold JJ 1993 Invasive lobular carcinoma of the breast: mammographic findings and extent of disease at diagnosis in 184 patients. American Journal of Roentgenology 161 957-960.
62. Kurtz JM, Jacquemier J, Torhorst J, Spitalier JM, Amalric R, Hunig R, Walther E, Harder F, Almendral A & Brandone H 1989 Conservation therapy for breast cancers other than infiltrating duct carcinoma. Cancer 63 1630-1635.
63. Lagendijk JH, Mullink H, van Diest PJ, Meijer GA & Meijer CJ 1999 Immunohistochemical differentiation between primary adenocarcinomas of the ovary and ovarian metastases of colonic and breast origin. Comparison between a statistical and an intuitive approach. Journal of Clinical Pathology 52 283-290.
64. Lee JS, Grant CS, Donohue JH, Crotty TB, Harmsen WS & Ilstrup DM 1995 Arguments against routine contralateral mastectomy or undirected biopsy for invasive lobular breast cancer. Surgery 118 640-647.
65. Li CI, Anderson BO, Porter P, Holt SK, Daling JR & Moe RE 2000a Changing incidence rate of invasive lobular breast carcinoma among older women. Cancer 88 2561-2569.
66. Li CI, Weiss NS, Stanford JL & Daling JR 2000b Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women. Cancer 88 2570-2577.
67. Li CI, Anderson BO, Daling JR & Moe RE 2003a Trend in incidence rates of invasive lobular and ductal breast carcinoma. JAMA 289 1421-1424.
68. Li CI, Anderson BO, Verkooijen HM, Fioretta G, Vlastos G, Morabia A, Schubert H, Sappino A, Pelte M & Schafer P 2003b Important increase of invasive lobular breast cancer incidence in Geneva, Switzerland. International Journal of Cancer 104 778-781.
69. Li CI, Malone KE, Porter PL, Weiss NS, Tang MC, CushingHaughen KL & Daling JR 2003c Relationships between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA 289 3254-3263.
70. Li CI, Moe RE & Daling JR 2003d Risk of mortality by histologic type of breast cancer among women aged 50 to 79 years. Archives of Internal Medicine 163 2149-2153.
71. Linderholm B, Adersson J, Lindh B, Beckman L, Erlanson M, Edin K, Tavelin B, Grankvist K & Henriksson R 2004 Overexpression of c-erbB-2 is related to higher expression of vascular endothelial growth factor (VEGF) and constitutes an independent prognostic factor in primary node-positive breast cancer after adjuvant systemic treatment. European Journal of Cancer 40 33-42.
72. Magnusson C, Persson I & Adami HO 2000 More about: effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. Journal of the National Cancer Institute 92 1183-1184.
73. Mai KT, Yazdi H & Isotalo PA 2000 Resection margin status in lumpectomy specimens of infiltrating lobular carcinoma. Breast Cancer Research and Treatment 60 29-33.
74. Mate TP, Carter D, Fischer DB, Hartman PV, McKhann C, Merino M, Prosnitz LR & Weisseberg JB 1986 A clinical and histopathologic analysis of the results of conservation surgery and radiation therapy in stage I and II breast cancer. Cancer 58 1995-2002.
75. Mathieu MC, Rouzier R, Llombart-Cussac A, Sideris L, Koscielny S, Travagli JP, Contesso G, Delaloge S & Spielmann M 2004 The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile. European Journal of Cancer 40 342-351.
76. Mendelson EB, Harris KM, Doshu N & Tobon H 1989 Infiltrating lobular carcinoma:mammographic patterns with pathologic correlation. American Journal of Roentgenology 153 265-271.
77. Mersin H, Yildirim E, Gulben K & Berberoglu U 2003 Is invasive lobular carcinoma different form invasive ductal carcinoma? European Journal of Surgical Oncology 29 390-395.
78. Molland JG, Donnellan M, Janu NC, Carmalt HL, Kennedy CW & Gillett DJ 2004 Infiltrating lobular carcinoma - a comparison of diagnosis, management and outcome with infiltrating duct carcinoma. Breast 13 389-396.
79. Newcomb PA, Titus-Ernstoff L, Egan KM, Trentham-Dietz A, Baron JA, Storer BE, Willett WC & Stampfer MJ 2002 Postmenopausal estrogen and progestin use in relation to breast cancer risk. Cancer Epidemiology, Biomarkers and Prevention 11 593-600.
80. Newcomer LM, Newcomb PA, Daling JR, Yasui Y & Potter JD 2003 Post-menopausal hormone use and risk of breast cancer by histologic type (United States). Cancer Causes and Control 14 225-233.
81. Pappo I, Meirshon I, Karni T, Siegelmann-Danielli N, Stahl-Kent V, Sandbank J, Wasserman I & Halevy A 2004 The characteristics of malignant breast tumors in hormone replacement therapy users versus nonusers. Annals of Surgical Oncology 11 52-58.
82. Paramagul CP, Helvie MA & Adler DD 1995 Invasive lobular carcinoma: sonographic appearance and role of sonography in improving diagnostic sensitivity. Radiology 195 231-234.
83. Park CC, Mitsumori M, Nixon A, Recht A, Connolly J, Gelman R, Silver B, Hetelekidis S, Abner A, Harris JR et al. 2000 Outcome at 8 years after breast-conserving surgery and radiation therapy for invasive breast cancer: influence of margin status and systemic therapy on local recurrence. Journal of Clinical Oncology 18 1668-1675.
84. Peiro G, Bornstein BA, Connolly JL, Gelman R, Hetelekidis S, Nixon AJ, Recht A, Silver B, Harris JR & Schnitt SJ 2000 The influence on infiltrating lobular carcinoma on the outcome of patients treated with breast-conserving surgery and radiation therapy. Breast Cancer Research and Treatment 59 49-54.
85. Persson I, Yuen J, Bergkvist L & Schairer C 1996 Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy - long-term follow-up of a Swedish cohort. International Journal of Cancer 67 337-332.
86. Poen JC, Tran L, Juillard G, Selch MT, Giuliano A, Silverstein M, Fingerhut A, Lewinsky B & Parker RG 1992 Conservation therapy for invasive lobular carcinoma of the breast. Cancer 69 2789-2795.
87. Pointon KS & Cunningham DA 1999 Ultrasound findings in pure invasive lobular carcinoma of the breast: comparison with matched cases of invasive ductal carcinoma of the breast. Breast 8 188-190.
88. Polednak A 2003 Bilateral synchronous breast cancer: a population-based study of characteristics, method of detection, and survival. Surgery 133 383-389.
89. Poole AJ, Li Y, Kim Y, Lin SC, Lee WH & Lee EY 2006 Prevention of BRCA1-mediated mammary tumorigenesis in mice by progesterone antagonist. Science 314 1467-1470.
90. Quan ML, Sclafani L, Heerdt S, Fey JV, Morris EA & Borgen PI 2003 Magnetic resonance imaging detects unsuspected disease in patients with invasive lobular cancer. Annals of Surgical Oncology 10 1048-1053.
91. Reeves GK, Beral V, Green J, Gathani T, Bull D & Million Women Study Collaborators 2006 Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis. Lancet Oncology 7 910-918.
92. Rissanen T, Tikkakoski T, Autio AL & Apaja-Sarkkinen M 1998 Ultrasonography of invasive lobular breast carcinoma. Acta Radiologica 39 285-291.
93. Rodenko GN, Harms SE, Pruneda JM, Farell RS, Evans WP, Copit DS, Krakos PA & Flamig DP 1996 MR imaging in the management before surgery of lobular carcinoma of the breast: correlation with pathology. American Journal of Roentgenology 167 1415-1419.
94. Rosen PP 2001 Invasive lobular cancer. In Rosen's Pathology of the Breast, pp 629-637. Ed PP Rosen. New York: Lippincott Williams & Wilkins.
95. Ross RK, Paganini-Hill A, Wan PC & Pike MC 2000 Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. Journal of the National Cancer Institute 92 328-332.
96. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC & Writing Group for the Women's Health Initiative Investigators 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 321-333.
97. Rouzier R, Mathieu M, Sideris L, Youmsi E, Rajan R, Garbay J, André F, Marsiglia H, Spielmann M & Delaloge S 2004 Breast-conserving surgery after neoadjuvant anthracycline-based chemotherapy for large breast tumors. Cancer 101 918-925.
98. Salvadori B, Biganzoli E, Veronesi P, Saccozzi R & Rilke F 1997 Conservative surgery for infiltrating lobular breast carcinoma. British Journal of Surgery 84 106-109.
99. Santiago RJ, Harris EE, Qinj L, Hwang WT & Solin LJ 2005 Similar long-term results of breast - conservation treatment for Stage I and II invasive lobular carcinoma compared with invasive ductal carcinoma of the breast: The University of Pennsylvania experience. Cancer 103 2447-2554.
100. Sastre-Garau X, Jouve M, Asselain B, Vincent-Salomon A, Beuzeboc P, Dorval T, Durand J, Fourquet A & Pouillart P 1996 Infiltrating lobular carcinoma of the breast. Clinicopathological analysis of 975 cases with references to data on conservative therapy and metastatic patterns. Cancer 77 113-120.
101. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L & Hoover R 2000 Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 283 485-491.
102. Schelfout K, Van Goethem M & Kersschot E 2004 Preoperative breast MRI in patients with invasive lobular breast cancer. European Radiology 14 1209-1216.
103. Schnitt SJ, Connolly JL, Recht A, Silver B & Harris JR 1989 Influence of infiltrating lobular histology on local tumour control in breast cancer patients treated with conservative surgery and radiotherapy. Cancer 64 448-454.
104. Silverstein MJ, Lewinsky BS, Waisman JR, Glerson ED, Colburn WJ, Senofsky GM & Gamagani P 1994 Infiltrating lobular carcinoma: is it different from infiltrating duct carcinoma? Cancer 73 1673-1677.
105. Singletary SE, Patel-Parekh L & Bland KI 2005 Treatment trends in early-stage invasive lobular carcinoma. A report from the National Cancer Data Base. Annals of Surgery 242 281-289.
106. Stefanick ML, Anderson GL, Margolis KL, Hendrix SL, Rodabough RJ, Paskett ED, Lane DS, Hubbell FA, Assaf AR, Sarto GE et al. 2006 Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 295 1647-1657.
107. Toikkanen S, Pylkkanen L & Joensuu H 1997 Invasive lobular carcinoma of the breast has better short- and long-term survival than invasive ductal carcinoma. British Journal of Cancer 76 1234-1240.
108. Tresserra F, Feu J, Grases PJ, Navarro B, Alegret X & Fernandez-Cid A 1999 Assessment of breast cancer size: sonographic and pathologic correlation. Journal of Clinical Ultrasound 27 485-491.
109. Tubiana-Hulin M, Stevens D, Lasry S, Guinebretiere JM, Bouita L, Cohen-Solal C, Cherel P & Rouesse J 2006 Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution. Annals of Oncology 17 1228-1233.
110. Tuttle TM, Colbert M, Christensen R, Ose KJ, Jones T, Wetherille R, Friedman J, Swenson K & McMasters KM 2002 Subareolar injection of 99mTc facilitates sentinel lymph node identification. Annals of Surgical Oncology 9 77-81.
111. Ugnat AM, Xie L, Morriss J, Semenciw R & Mao Y 2004 Survival of women with breast cancer in Ottawa, Canada: variation with age, stage, histology, grade and treatment. British Journal of Cancer 90 1138-1143.
112. Veltman J, Boetes C, van Die L, Bult P, Blickman JG & Barentsz JO 2006 Mammographic detection and staging of invasive lobular carcinoma. Clinical Imaging 30 94-98.
113. Vo TN, Meric Bernstam F, Yi M, Buchholtz TA, Ames FC, Kueree HM, Bedrosian I & Hunt KK 2006 Outcomes of breast-conservation therapy for invasive lobular carcinoma are equivalent to those for invasive ductal carcinoma. American Journal of Surgery 192 552-555.
114. Warneke J, Berger R, Johnson C, Stea D & Villar H 1996 Lumpectomy and radiation treatment for invasive lobular carcinoma of the breast. American Journal of Surgery 172 496-500.
115. Watson L 2001 Breast cancer: diagnosis, treatment and prognosis. Radiologic Technology 73 45-61.
116. Weiss ML, Fowble BL, Solin LJ, Tien Yeh I & Schultz DJ 1992 Outcome of conservative therapy for invasive breast cancer by histologic subtype. International Journal of Radiation Oncology, Biology, Physics 23 941-947.
117. Weiss LK, Burkman RT, Cushing-Haugen KL, Voigt LF, Simon MS, Daling JR, Norman SA, Bernstein L, Ursin G & Marchbanks PA 2002 Hormone replacement therapy regimens and breast cancer risk. Obstetrics and Gynecology 100 1148-1158.
118. White JR, Gustafson GS, Wimbish K, Ingold JA, Lucas RJ, Levine AJ, Matter RA, Martinez A & Vicini FA 1994 Conservative surgery and radiation therapy for infiltrating lobular carcinoma of the breast. Cancer 74 640-647.
119. Winchester DJ, Chang HR, Graves TA, Menck HR, Bland KI & Winchester DP 1998 A comparative analysis of lobular and ductal carcinoma of the breast: presentation, treatment, and outcomes. Journal of the American College of Surgeons 186 416-422.
120. Wysowski DK & Governale LA 2005 Use of menopausal hormones in the United States, 1992 through June, 2003. Pharmacoepidemiology and Drug Safety 14 171-176.
121. Wysowski DK, Golden L & Burke L 1995 Use of menopausal estrogens and medroxyprogesterone in the United States, 1982-1992. Obstetrics and Gynecology 85 6-10.